XTL Biopharmaceuticals Ltd.
Price Action
Technical Summary
WEAKENINGXTL Biopharmaceuticals Ltd. is in a technical downtrend, trading below key resistance levels with a broken trend structure. Relative strength is weak (RS Rating: 16), showing significant lag compared to the market leaders. Earnings growth of 20% provides fundamental context to the price action. Investors should exercise caution due to high volatility (156% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $2.53 | +17.82% | ABOVE |
| 50 SMA | $2.64 | +12.80% | ABOVE |
| 100 SMA | $2.69 | +10.64% | ABOVE |
| 150 SMA | $2.92 | +2.02% | ABOVE |
| 200 SMA | $3.33 | -10.60% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is XTLB in an uptrend right now?
XTLB has a trend score of 1/4 based on Minervini's Stage Analysis. Currently showing broken structure - 1 of 4 trend criteria are met.
Is XTLB overbought or oversold?
XTLB's RSI (14) is 64. The stock is in neutral territory, neither overbought nor oversold.
Is XTLB outperforming the market?
XTLB has a Relative Strength (RS) Rating of 16 out of 99. XTLB is currently lagging the broader market.
Where is XTLB in its 52-week range?
XTLB is trading at $2.98, which is 29% of its 52-week high ($10.28) and 21% above its 52-week low ($1.05).
How volatile is XTLB?
XTLB has a Beta of 1.46 and 52-week volatility of 156%. It's more volatile than the S&P 500 - expect bigger swings.